The overall objective is to develop a series of data bases on which assessment of potential health consequences, especially total burden of environmental carcinogens and mutagens, resulting from utilization of fossil fuels can be made more objectively and with greater precision than is currently possible. The program of research has the objective of determining the character and range of potential health effects associated with several technologies for fossil fuel combustion by relating evaluations of a variety of biological responses to critical operating parameters characterisistic of existing and alternative combustion equipment. The ultimate aim is to define conditions of combustion for each of several fuel types which result in the emission of minimal amounts of substances with mutagenic and/or carcinogenic properties. This objective is being approached through the following lines of investigation: (1) Conducting parametric combustion studies using laboratory and larger-scale combustors to determine effects of temperature, equivalence ratio and fuel type on the formation of particulates and polycyclic compounds. (2) Subjecting selected samples from the combustion experiments to exhaustive chemical analysis. (3) Evaluating the biological and biochemical properties of selected samples produced under defined combustion conditions with respect to: mutagenicity in bacteria and human cells; and ability to form covalent adducts with nucleic acids when activated in vitro and in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Program Projects (P01)
Project #
5P01ES001640-09
Application #
3095835
Study Section
Environmental Health Sciences Review Committee (EHS)
Project Start
1978-07-01
Project End
1988-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
9
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
Organized Research Units
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Tomita-Mitchell, Aoy; Ling, Losee Lucy; Glover, Curtis L et al. (2003) The mutational spectrum of the HPRT gene from human T cells in vivo shares a significant concordant set of hot spots with MNNG-treated human cells. Cancer Res 63:5793-8
Tomita-Mitchell, A; Kat, A G; Marcelino, L A et al. (2000) Mismatch repair deficient human cells: spontaneous and MNNG-induced mutational spectra in the HPRT gene. Mutat Res 450:125-38
Durant, J L; Lafleur, A L; Busby Jr, W F et al. (1999) Mutagenicity of C24H14 PAH in human cells expressing CYP1A1. Mutat Res 446:1-14
Wang, J S; He, X; Mulder, P P et al. (1999) Comparative tumorigenicity of the cyclopenta-fused polycyclic aromatic hydrocarbons aceanthrylene, dihydroaceanthrylene and acephenanthrylene in preweanling CD-1 and BLU:Ha mouse bioassays. Carcinogenesis 20:1137-41
Busby Jr, W F; Smith, H; Plummer, E F et al. (1997) Mutagenicity of cyclopenta-fused polynuclear aromatic hydrocarbons and a non-polar fraction from a fuel combustion sample in a Salmonella forward mutation assay without exogenous metabolic activation. Mutat Res 391:117-25
Busby Jr, W F; Smith, H; Crespi, C L et al. (1997) Mutagenicity of the atmospheric transformation products 2-nitrofluoranthene and 2-nitrodibenzopyranone in Salmonella and human cell forward mutation assays. Mutat Res 389:261-70
Durant, J L; Busby Jr, W F; Lafleur, A L et al. (1996) Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosols. Mutat Res 371:123-57
Palotas, A B; Rainey, L C; Feldermann, C J et al. (1996) Soot morphology: an application of image analysis in high-resolution transmission electron microscopy. Microsc Res Tech 33:266-78
Wang, J S; Busby Jr, W F (1996) Bacterial and human cell mutagenicity and mouse lung tumorigenicity of the oxygenated polynuclear aromatic hydrocarbon phenalenone. Fundam Appl Toxicol 33:212-9
Wang, J S; Busby, W F; Wogan, G N (1995) Tissue distribution of DNA adducts in pre-weanling BLU:Ha mice treated with a tumorigenic dose of fluoranthene. Cancer Lett 92:9-19

Showing the most recent 10 out of 65 publications